Insights into US public biotech sector using patenting trends
Article Abstract:
An analysis of the trends in patenting by publicly traded biotech firms in the decade 1995-2005 from the data collected by US Patent and Trade Organization (USPTO) website is presented. The study shows the growing importance of public small-and medium-sized enterprises (SMEs), compared with large biotech firms, in developing the intellectual property (IP) knowledge base.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Navigating the future(s) of biotech intellectual property
Article Abstract:
The role of intellectual property (IP) in biotech is gaining utmost importance as the sector faces the need both to protect innovations and to open them up. The risk to the biotech industry will increase if the public and nonprofit sector will put together pressure for bigger changes in the patent system.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Trendspotting: A shift in intellectual property focus
Article Abstract:
Developments in intellectual property and their effect on the life science industry are reported. The diverse legal issues in financings, licensing and collaboration transactions, and the intellectual property protection and strategies that life science companies and investors face is addressed.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Antiinfective biotechs face partnering gap. A taste of the future
- Abstracts: Toll-like receptor therapies compete to reduce side effects. Belated approval of first recombinant protein from animal
- Abstracts: Robert Tjian. Tracking down tissues. Cellulosic ethanol booms despite unproven business models
- Abstracts: Gold in the ivory tower: Equity rewards of outlicensing. Who took the tech out of biotech? The hermit crab solution